Search Results - "Zeghondy, Jean"

Provision of Lifestyle Recommendations to Cancer Patients: Results of a Nationally Representative Survey of Hematologists/Oncologists by Massoud, Marcel, Ikdais, Werner, Zeghondy, Jean, Saad, Aline

“…Adopting a healthy lifestyle during cancer treatment enhances patients’ outcomes. The purpose of this study is to evaluate the current practices and attitudes…”
Get full text

Telehealth in breast cancer following the coronavirus disease 2019 pandemic by Zeghondy, Jean, Rassy, Elie, Lapidari, Pietro, Eid, Roland, Pistilli, Barbara

“…Breast cancer (BC) is the second most diagnosed cancer in 2018 with around 2.3 million cases globally in 2020. In March 2020 and after its worldwide spread,…”
Get full text

AML-212 Older Adult Patient With AML and Limited Access to Drugs Achieves Complete Remission While Treated With Azacitidine, Low-Dose Venetoclax, and an Azole by Zeghondy, Jean, Sakr, Riwa, Massoud, Marcel

Get full text

Azacitidine combined with low dose Venetoclax and Azole in treatment-naive, elderly patient with acute myeloid leukemia: A case report by Jean Zeghondy, R. Sakr, M. Massoud

“…Introduction: Acute Myeloid Leukemia (AML) is the most common acute leukemia in adults with an increasing incidence with age. Patients older than 65 years…”
Get full text

Efficacy of tucatinib+trastuzumab+capecitabine (TTC) after trastuzumab-deruxtecan (T-DXd) exposure in Her2-positive metastatic breast cancer: A French multicentre retrospective study by Frenel, Jean-Sebastien, Zeghondy, Jean, Guerin, Catherine, Mailliez, Audrey, Volant, Elsa, Poumeaud, Francois, Patsouris, Anne, Arnedos, Monica, Bailleux, Caroline, Cabal, Julie, Galland, Loick, De nonneville, Alexandre, Guiu Lahaye, Severine, Dalenc, Florence, Pistilli, Barbara, Bachelot, Thomas, Martin, Pierre, Bocquet, Francois, Larrouquere, Louis, Loirat, Delphine

“…1014 Background: Recent guidelines have positioned T-DXd as a preferred treatment in the second line setting for HER2+ metastatic breast cancer (MBC). TTC is…”
Get full text

Survival Pattern of Hairy Cell Leukemia Patients in the Last 20 Years in Lebanon by Nasr, Fadi, Zeghondy, Jean, Salem, Mansour, Rizk, Rita, Haidar, Nour, Chahine, Georges

Get full text

Development and Validation of an Inflammatory Prognostic Index to Predict Outcomes in Advanced/Metastatic Urothelial Cancer Patients Receiving Immune Checkpoint Inhibitors by Mokbel, Sara, Baciarello, Giuilia, Lavaud, Pernelle, Omlin, Aurelius, Calabrò, Fabio, Cathomas, Richard, Aeppli, Stefanie, Parent, Pauline, Giannatempo, Patrizia, Koster, Kira-Lee, Appel, Naara, Gonnet, Philippe, Angius, Gesuino, Tsantoulis, Petros, Arkenau, Hendrick-Tobias, Cattrini, Carlo, Messina, Carlo, Zeghondy, Jean, Morelli, Cristina, Loriot, Yohann, Formica, Vincenzo, Patrikidou, Anna

“…Immune checkpoint inhibitors (ICIs) improve overall survival (OS) in advanced/metastatic urothelial cancer (a/mUC) patients. Preliminary evidence suggests a…”
Get full text

Survival Pattern of Non-Hodgkin Lymphoma Patients in the Last 34 Years in Lebanon by Massoud, Marcel, Antoun, Leony, Zeghondy, Jean, Tarabay, Anthony, Nourie, Nicole, Nasr, Fadi, Chahine, Georges

Get full text

Survival of Multiple Myeloma in the Lebanese Population between January 2005 and December 2017 by Massoud, Marcel, Tarabay, Anthony, Zeghondy, Jean, Rached, Layal, Kerbage, Fouad, Nasr, Fadi, Chahine, Georges

Get full text

Comparison of the Efficacy Between RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) and Dose Dense Chemotherapy Regimens (RCHOP-14, R-DHAP- R-EPOCH) on Survival as a First Line Treatment in Lebanese Patients with Non-Hodgkin Lymphoma by Antoun, Leony, Touma, Elsie, Nasr, Fadi, Massoud, Marcel, Rizk, Rita, Salem, Mansour, Zeghondy, Jean, Hallit, Souheil, Chahine, Georges

Get full text

Survival Pattern of Hodgkin Lymphoma Patients in the Last 25 Years in Lebanon by Massoud, Marcel, Kerbage, Fouad, Nehme, Joseph, Sakr, Riwa, Rached, Layale, Zeghondy, Jean, Nasr, Fady, Chahine, Georges

“…We retrospectively compared the overall survival in HL over 3 different decades in Lebanon. Patients were divided into 3 groups according to period of…”
Get full text

Tucatinib Combination Treatment After Trastuzumab-Deruxtecan in Patients With ERBB2-Positive Metastatic Breast Cancer by Frenel, Jean-Sebastien, Zeghondy, Jean, Guérin-Charbonnel, Catherine, Mailliez, Audrey, Volant, Elsa, Poumeaud, François, Patsouris, Anne, Arnedos, Monica, Bailleux, Caroline, Cabal, Julie, Galland, Loick, de Nonneville, Alexandre, Guiu, Séverine, Dalenc, Florence, Pistilli, Barbara, Bachelot, Thomas, Pierga, Jean-Yves, Le Du, Fanny, Bocquet, François, Larrouquere, Louis, Loirat, Delphine

“…Little is known regarding the outcomes associated with tucatinib combined with trastuzumab and capecitabine (TTC) after trastuzumab-deruxtecan exposure among…”
Get full text

Real-life Experience for Integration of PET-CT in the Treatment of Hodgkin Lymphoma in Lebanon by Sakr, Riwa, Massoud, Marcel, Kerbage, Fouad, Rached, Layale, Zeghondy, Jean, Akoury, Elie, Nasr, Fady, Chahine, Georges

“…Hodgkin lymphoma (HL) is a highly curable disease. We analyzed the data regarding the usage of PET-CT at diagnosis, during treatment (interim PET), and at the…”
Get full text

Survival Pattern of Hodgkin's Lymphoma Patients in the Last 25 Years in Lebanon by Massoud, Marcel, Kerbage, Fouad, Nehme, Joseph, Sakr, Riwa, Rached, Layale, Zeghondy, Jean, Nasr, Fadi, Chahine, Georges

Get full text

Real Life Experience for Integration of PET-CT in the Treatment of HL in Lebanon by Sakr, Riwa, Massoud, Marcel, Kerbage, Fouad, Rached, Layale, Zeghondy, Jean, Nasr, Fadi, Chahine, Georges

Get full text